Rafael Holdings Inc - Ordinary Shares - Class B Stock News

NEWARK, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that it will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on Monday, November 9, 2026 at 3:55 p.m. ET, and host one-on-one meetings with institutional investors.

NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026.

NDA supported by the Phase 3 TransportNPC ™ study, data from earlier clinical studies, and an overall survival analysis versus external registry controls

Trappsol ® Cyclo™ did not achieve statistical significance but demonstrated a directionally favorable treatment effect versus placebo on the primary endpoint of change in the 4-domain NPC Clinical Severity Scale (4DNPCSS) at Week 96 A prespecified analysis in patients receiving background miglustat and/or leucine therapy, representing approximately 83% of the study population, showed a statisti...

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026.

Topline results are expected to be announced in second half of calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 The company has received acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed NEWARK, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced th...